Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report
- PMID: 29634552
- DOI: 10.1213/XAA.0000000000000726
Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report
Abstract
Opioid-induced constipation (OIC) is a common gastrointestinal adverse effect of opioids, which can severely affect compliance and adherence to pain medication regimens and quality of life. Naloxegol has demonstrated efficacy against OIC in several studies involving patients with nonmalignant chronic pain. Here we report efficacy and tolerability of naloxegol in a 68-year-old patient with metastatic lung cancer and severe pain, treated with opioids, who presented with OIC resistant to traditional measures. Addition of naloxegol produced rapid improvement in his OIC symptoms and no apparent adverse effects while taking extended-release morphine 130 mg orally every 12 hours.
Similar articles
-
Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.Adv Ther. 2016 Aug;33(8):1331-46. doi: 10.1007/s12325-016-0365-y. Epub 2016 Jun 24. Adv Ther. 2016. PMID: 27342744 Free PMC article. Clinical Trial.
-
Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.Aliment Pharmacol Ther. 2014 Oct;40(7):771-9. doi: 10.1111/apt.12899. Epub 2014 Aug 12. Aliment Pharmacol Ther. 2014. PMID: 25112584 Clinical Trial.
-
Naloxegol for the treatment of opioid-induced constipation.Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):855-61. doi: 10.1586/17474124.2014.939629. Epub 2014 Sep 15. Expert Rev Gastroenterol Hepatol. 2014. PMID: 25220391 Review.
-
A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.J Opioid Manag. 2016 Nov/Dec;12(6):405-419. doi: 10.5055/jom.2016.0360. J Opioid Manag. 2016. PMID: 28059433 Clinical Trial.
-
Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.Drugs Today (Barc). 2015 Aug;51(8):479-89. doi: 10.1358/dot.2015.51.8.2364896. Drugs Today (Barc). 2015. PMID: 26380386 Review.
Cited by
-
Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis.BMJ Support Palliat Care. 2021 Mar;11(1):25-31. doi: 10.1136/bmjspcare-2020-002249. Epub 2020 May 6. BMJ Support Palliat Care. 2021. PMID: 32376758 Free PMC article.
-
One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study.BMJ Support Palliat Care. 2023 Dec 7;13(e2):e318-e326. doi: 10.1136/bmjspcare-2020-002816. BMJ Support Palliat Care. 2023. PMID: 33707299 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical